| Published Version Download ( PDF | 552kB) | License: Creative Commons Attribution 4.0 |
Paclitaxel, Imatinib and 5-Fluorouracil Increase the Unbound Fraction of Flucloxacillin In Vitro
Stolte, Maximilian, Ali, Weaam, Jänis, Janne
, Gessner, Andre and El-Najjar, Nahed
(2020)
Paclitaxel, Imatinib and 5-Fluorouracil Increase the Unbound Fraction of Flucloxacillin In Vitro.
Antibiotics 9 (6), p. 309.
Date of publication of this fulltext: 16 Jun 2020 15:17
Article
DOI to cite this document: 10.5283/epub.43351
Abstract
Flucloxacillin (FLU), an isoxazolyl penicillin, is widely used for the treatment of different bacterial infections in intensive care units (ICU). Being highly bound to plasma proteins, FLU is prone to drug-drug interactions (DDI) when administered concurrently with other drugs. As FLU is binding to both Sudlow's site I and site II of human serum albumin (HSA), competitive and allosteric ...
Flucloxacillin (FLU), an isoxazolyl penicillin, is widely used for the treatment of different bacterial infections in intensive care units (ICU). Being highly bound to plasma proteins, FLU is prone to drug-drug interactions (DDI) when administered concurrently with other drugs. As FLU is binding to both Sudlow's site I and site II of human serum albumin (HSA), competitive and allosteric interactions with other drugs, highly bound to the same sites, seem conceivable. Knowledge about interaction(s) of FLU with the widely used anticancer agents paclitaxel (PAC), imatinib (IMA), and 5-fluorouracil (5-FU is scarce. The effects of the selected anticancer agents on the unbound fraction of FLU were evaluated in pooled plasma as well as in HSA and alpha-1-acid glycoprotein (AGP) samples, the second major drug carrier in plasma. FLU levels in spiked samples were analyzed by LC-MS/MS after ultrafiltration. Significant increase in FLU unbound fraction was observed when in combination with PAC and IMA and to a lesser extent with 5-FU. Furthermore, significant binding of FLU to AGP was observed. Collectively, this is the first study showing the binding of FLU to AGP as well as demonstrating a significant DDI between PAC/IMA/5-FU and FLU.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Antibiotics | ||||
| Publisher: | MDPI | ||||
|---|---|---|---|---|---|
| Place of Publication: | BASEL | ||||
| Volume: | 9 | ||||
| Number of Issue or Book Chapter: | 6 | ||||
| Page Range: | p. 309 | ||||
| Date | 8 June 2020 | ||||
| Institutions | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene | ||||
| Identification Number |
| ||||
| Keywords | DRUG-DRUG INTERACTIONS; HUMAN SERUM-ALBUMIN; CRITICALLY-ILL PATIENTS; PROTEIN-BINDING; CANCER-PATIENTS; ALPHA-1-ACID GLYCOPROTEIN; CLINICAL-PHARMACOLOGY; ALLOSTERIC MODULATION; ANTICANCER DRUGS; PHARMACOKINETICS; albumin; alpha-1-acid glycoprotein; drug-drug interactions; anti-infective agents; ultrafiltration; cancer | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| URN of the UB Regensburg | urn:nbn:de:bvb:355-epub-433514 | ||||
| Item ID | 43351 |
Download Statistics
Download Statistics